A comprehensive review on the efficacy of several pharmacologic agents for the treatment of COVID-19
Simple Summary Treatments for coronavirus disease-2019 (COVID-19) have utilized a
variety of medications, including antivirals, immunomodulators, and other therapeutics such …
variety of medications, including antivirals, immunomodulators, and other therapeutics such …
[HTML][HTML] Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments
SW Zhao, YM Li, YL Li, C Su - World Journal of Gastroenterology, 2023 - ncbi.nlm.nih.gov
Abstract The coronavirus disease 2019 (COVID-19) pandemic has been a serious threat to
global health for nearly 3 years. In addition to pulmonary complications, liver injury is not …
global health for nearly 3 years. In addition to pulmonary complications, liver injury is not …
The SARS-CoV-2 S1 spike protein promotes MAPK and NF-kB activation in human lung cells and inflammatory cytokine production in human lung and intestinal …
The coronavirus disease 2019 (COVID-19) pandemic began in January 2020 in Wuhan,
China, with a new coronavirus designated SARS-CoV-2. The principal cause of death from …
China, with a new coronavirus designated SARS-CoV-2. The principal cause of death from …
COVID-19: An Update on the Latest Therapeutic Agents
The COVID-19 pandemic has plagued the world for over three years since discovering the
causative virus, SARS-CoV-2, in China. The rampant spread of the virus led to the loss of …
causative virus, SARS-CoV-2, in China. The rampant spread of the virus led to the loss of …
NLRP3, the inflammasome and COVID-19 infection
Abstract Severe coronavirus disease 2019 (COVID-19) is characterized by respiratory
failure, shock or multiorgan dysfunction, often accompanied by systemic hyperinflammation …
failure, shock or multiorgan dysfunction, often accompanied by systemic hyperinflammation …
[HTML][HTML] Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system
Despite tremendous global efforts since the beginning of the COVID-19 pandemic, still only
a limited number of prophylactic and therapeutic options are available. Although vaccination …
a limited number of prophylactic and therapeutic options are available. Although vaccination …
[HTML][HTML] Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and Prevention
Abstract Coronavirus disease 2019 (COVID-19) has had profound effects on the health of
individuals and on healthcare systems worldwide. While healthcare workers on the …
individuals and on healthcare systems worldwide. While healthcare workers on the …
Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19
S Chen, C Zhang, D Chen, L Dong, T Chang… - Frontiers in …, 2023 - frontiersin.org
Nowadays, people have relaxed their vigilance against COVID-19 due to its declining
infection numbers and attenuated virulence. However, COVID-19 still needs to be concern …
infection numbers and attenuated virulence. However, COVID-19 still needs to be concern …
Anakinra—An Interleukin-1 Receptor Antagonist for COVID-19
Background: Coronavirus disease (COVID-19) caused by SARS-CoV-2 virus caused a
global pandemic in 2019. There are limited pharmacologic options available. The Food and …
global pandemic in 2019. There are limited pharmacologic options available. The Food and …
Beyond an inflammatory mediator: Interleukin‐1 in neurophysiology
TS Lima - Experimental Physiology, 2023 - Wiley Online Library
Since its discovery in the early 1940s, the interleukin‐1 (IL‐1) cytokine family has been
associated primarily with acute and chronic inflammation. The family member IL‐1β is …
associated primarily with acute and chronic inflammation. The family member IL‐1β is …